0000819050-20-000143.txt : 20200716 0000819050-20-000143.hdr.sgml : 20200716 20200616083702 ACCESSION NUMBER: 0000819050-20-000143 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200616 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Brickell Biotech, Inc. CENTRAL INDEX KEY: 0000819050 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 930948554 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 5777 CENTRAL AVENUE STREET 2: SUITE 102 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (720) 505-4755 MAIL ADDRESS: STREET 1: 5777 CENTRAL AVENUE STREET 2: SUITE 102 CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: VICAL INC DATE OF NAME CHANGE: 19940211 CORRESP 1 filename1.htm Document


Oppenheimer & Co. Inc.
85 Broad Street
New York, NY 10004

June 16, 2020
 
 
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
 
 
Re:
Brickell Biotech, Inc. (the “Company”)
Registration Statement on Form S-1 (File No. 333-238298)

Ladies and Gentlemen:
 
In connection with the above-captioned registration statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Oppenheimer & Co. Inc., as the representative of the underwriters, hereby joins in the request of the Company that the effective date of such registration statement be accelerated to 4:00 p.m. (New York time) on June 17, 2020, or as soon thereafter as practicable.
 
In making this request the undersigned acknowledges that the underwriters are aware of their obligations under the Act as they relate to the public offering of securities pursuant to the registration statement.
 
[Signature Page Follows]
 
 



Very truly yours,
 
OPPENHEIMER & CO. INC.
As the Representative of the Underwriters
 
 
By:/s/ Michael A. Margolis, R.Ph. 
Name: Michael A. Margolis, R.Ph. 
Title:Managing Director, Co-Head of Healthcare Investment Banking 
 
 
-2-